Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : Predictive Marker and Mechanism

Centre Hospitalier Universitaire de Nice

Status: Terminated

Conditions: Peritoneal Carcinomatosis

Treatments: Biological: peripheral venous blood samples

Study type: Interventional

Funder types: Other

Identifiers

NCT02803515

16-AOI-11

Details and patient eligibility

About

Peritoneal carcinomatosis (PC) is the stage III of the FIGO ovarian cancer staging. It corresponds to an advanced stage with a relative 5 year survival rate of 52%. The multimodal treatment approach combines neoadjuvant chemotherapy, cytoreductive surgery of macroscopic lesions, and hyperthermic intraperitoneal chemotherapy (HIPEC). It has significantly improved survival rate in patients with ovarian PC and decreased recurrence and mortality rate by 21%. The efficacy of HIPEC is based on chemotherapy potentiated by the hyperthermia (43°). However, the cellular mechanisms involved are not fully understood, but they include cell death pathways and heat shock proteins (Hsp70 and Hsp90). RICCI et al. showed, based on pre-clinical models, that the efficacy of HIPEC was partly due to the overexpression and exposure of HSP90 on the cell surface leaded to an anti-cancer immune response. The aims of this study are to validate these findings in tissue samples of patients with ovarian PC. We will constitute a bank of isolated tumor samples before and after HIPEC and measure postoperative HSP90 serum levels in order to establish if they are predictive of a response. HSPs expression on the cancer cell surface will be determined by flow cytometry. Forty-four patients will be included. Elucidating the underlying mechanisms of HIPEC will broaden therapeutic possibilities including the use of new immunotherapy. The multimodal approach could improve the efficacy of HIPEC with a minimal systemic toxicity.

Enrollment: 12 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females over 18 years.
• Indication of Hyperthermic Intra Peritoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis from ovarian origin
• Obtaining written informed consent and signed for participation in the study and conservation of samples taken.
• Affiliation to a social security scheme.

Non-inclusion criteria

• Major patients protected by law or deprived of liberty.
• Patients pregnant women in labor or breastfeeding.
• Refusal of participation
• Another cause of peritoneal carcinomatosis

Exclusion criteria

• consent withdrawn

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

Patient with HIPEC

Experimental group

Treatment:

Biological: peripheral venous blood samples

Patient without HIPEC

Sham Comparator group

Treatment:

Biological: peripheral venous blood samples